ERYPAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ERYPAR (ERYPAR).
Erypoietin receptor agonist; stimulates erythropoiesis by binding to erythropoietin receptors on erythroid progenitor cells.
| Metabolism | Metabolized via receptor-mediated internalization and degradation; not extensively metabolized by liver enzymes. |
| Excretion | Primarily renal excretion of unchanged drug (~75%) and metabolites; biliary/fecal elimination accounts for ~20% |
| Half-life | Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to >10 hours in severe renal impairment |
| Protein binding | ~30% bound, primarily to albumin |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution mainly into extracellular fluid |
| Bioavailability | Oral: ~80% (fasting); food may reduce absorption |
| Onset of Action | Oral: 1-2 hours; Intravenous: within 30 minutes |
| Duration of Action | 12-24 hours, depending on dose and infection severity; clinical effect may persist beyond drug detection |
Intravenous: 100 mg every 12 hours for 7 to 14 days.
| Dosage form | TABLET |
| Renal impairment | For GFR 15 to 29 mL/min: 100 mg every 24 hours. For GFR <15 mL/min or hemodialysis: 100 mg every 48 hours. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required. Monitor renal function closely and adjust based on creatinine clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ERYPAR (ERYPAR).
| Breastfeeding | Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). Considered compatible with breastfeeding. Monitor infant for diarrhea, rash, or oral thrush. Use with caution in neonates <2 weeks due to association with infantile hypertrophic pyloric stenosis. |
| Teratogenic Risk | Erypar (erythromycin) is generally considered low risk in pregnancy. Animal studies show no teratogenicity; human data do not indicate increased malformations. First trimester: possible but unconfirmed association with pyloric stenosis. Second/third trimester: safe for indicated uses (e.g., chlamydia, preterm PROM prophylaxis). Avoid erythromycin estolate due to cholestatic hepatitis risk. |
■ FDA Black Box Warning
Increased risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and tumor progression or recurrence when used in cancer patients. Use the lowest dose sufficient to avoid red blood cell transfusion.
| Serious Effects |
Uncontrolled hypertension; history of pure red cell aplasia following erythropoiesis-stimulating agent therapy; known hypersensitivity to recombinant erythropoietin or any components.
| Precautions | Increased mortality and serious cardiovascular events when targeting hemoglobin >11 g/dL; increased risk of thrombosis; seizures; potential for tumor progression; pure red cell aplasia due to anti-erythropoietin antibodies; severe allergic reactions; hypertension; iron deficiency. |
| Food/Dietary | No clinically significant food interactions. However, erythromycin absorption may be decreased by high-fat meals; take on an empty stomach (1 hour before or 2 hours after meals) for optimal absorption. Avoid alcohol during therapy due to sulfisoxazole component (disulfiram-like reaction may occur with erythromycin). |
Loading safety data…
| Fetal Monitoring | Monitor maternal liver enzymes (risk of cholestatic hepatitis with estolate ester). Monitor for signs of superinfection (C. difficile). Fetal monitoring: no specific, but assess for preterm labor if used for PROM. Auditory monitoring if high doses >4 g/day (ototoxicity). |
| Fertility Effects | No known adverse effects on fertility in humans. Animal studies do not report impaired reproduction. May be used safely for infections that could impair fertility (e.g., chlamydia). |
| Clinical Pearls | ERYPAR is a combination product containing erythromycin (macrolide antibiotic) and sulfisoxazole (sulfonamide) used for otitis media in children. Monitor for hypersensitivity reactions, especially in patients with sulfonamide allergy. Erythromycin can cause QT prolongation; avoid concurrent use with other QT-prolonging agents. Use with caution in hepatic impairment due to erythromycin metabolism. |
| Patient Advice | Take exactly as prescribed; complete the full course even if symptoms improve. · Do not use if you have a history of allergy to erythromycin, sulfonamides, or related drugs. · Report any rash, fever, joint pain, or unusual bruising/bleeding immediately. · May cause diarrhea; if severe or bloody, consult doctor (possible C. diff colitis). · Avoid sun exposure and use sunscreen; sulfonamides increase photosensitivity. · Shake oral suspension well before each dose; use measuring device for accurate dosing. |